In this episode, we explore how endoscopic eradication therapy has revolutionized the management of Barrett’s esophagus, largely replacing esophagectomy as the standard of care for high-grade dysplasia and early intramucosal cancer. We break down the crucial "resect and ablate" strategy, where endoscopists first remove visible nodules using endoscopic mucosal resection (EMR) or submucosal dissection (ESD) to accurately stage the disease. We then discuss how the remaining flat, dysplastic tissue is eliminated using radiofrequency ablation (RFA) or cryotherapy to prevent progression to esophageal adenocarcinoma. The conversation also highlights the vital role of expert pathology review in confirming low-grade dysplasia due to high rates of misdiagnosis, as well as the emergence of non-endoscopic screening tools like swallowable cell-collection devices. Finally, we look at updated guidelines moving away from "one-size-fits-all" surveillance toward personalized intervals based on risk stratification and prior treatment success.

In this episode, we explore Carcinoma in Situ (CIS) of the bladder, a flat, high-grade malignancy confined to the inner lining that carries a significant risk of progression to muscle-invasive disease. We discuss the diagnostic challenges of this often invisible lesion, emphasizing the role of urine cytology and enhanced imaging techniques like blue light cystoscopy. Finally, we cover management strategies, including the standard use of intravesical BCG immunotherapy, the role of radical cystectomy for high-risk failures, and emerging treatments for BCG-unresponsive disease such as pembrolizumab and nadofaragene firadenovec.

Carcinoma in Situ (CIS) is considered the primary clinical entity classified as non-papillary urothelial carcinoma. While the terms describe the same lesion in the context of non-invasive disease, "non-papillary" specifically refers to the tumor's morphological growth pattern, whereas CIS is the specific diagnosis.

Key distinctions regarding CIS as a non-papillary cancer include:

• Morphology (Shape): Unlike the more common papillary carcinomas, which form finger-like projections extending into the bladder's hollow center, CIS lesions are flat and grow along the surface of the bladder lining (urothelium). They often appear as velvety, red patches rather than exophytic masses.
• Classification: In the TNM staging system, CIS is classified as Tis (flat, non-invasive carcinoma), distinguishing it from Ta tumors, which are non-invasive but papillary in structure.
• Biological Pathway: Urothelial carcinoma is often categorized into two development pathways: the papillary pathway and the non-papillary pathway. CIS represents the non-papillary track; while it is confined to the lining (non-muscle invasive), it is universally high-grade and carries a high risk of progressing to muscle-invasive disease compared to low-grade papillary tumors.
• Invasive Potential: While CIS is the non-invasive form of non-papillary cancer, invasive bladder cancers (T2 and higher) can also be non-papillary (solid or sessile) in nature. Consequently, CIS is often viewed as a precursor to these more aggressive, invasive non-papillary tumors.

In this episode, we examine hantaviruses, a family of rodent-borne pathogens that cause severe human diseases including Hemorrhagic Fever with Renal Syndrome (HFRS) and Hantavirus Pulmonary Syndrome (HPS). We discuss the global epidemiology of these viruses, their transmission through aerosolized rodent excreta, and the current landscape of prevention strategies, ranging from rodent control to the use of inactivated vaccines in China and South Korea.

In this episode, we explore the evolving treatment landscape for Follicular Lymphoma, contrasting the superior progression-free survival of R-bendamustine against standard R-CHOP in frontline therapy. We discuss groundbreaking ASH 2025 data on epcoritamab combinations and CAR T-cell therapies like liso-cel for relapsed disease, alongside the safety challenges facing PI3K inhibitors and the approval of EZH2 inhibitors like tazemetostat. Finally, we examine the molecular underpinnings of the disease, including the hallmark t(14;18) translocation and the utility of FLIPI scores for risk stratification.

In this episode, we explore 22q11.2 deletion syndrome (22q11.2DS), the most common human microdeletion often historically diagnosed as DiGeorge or Velocardiofacial syndrome. We discuss how the haploinsufficiency of genes on chromosome 22—most notably TBX1—disrupts embryonic development, leading to a complex multisystem phenotype that includes congenital heart defects, immune deficiency, palatal abnormalities, and hypocalcaemia. We also examine the significant neurodevelopmental and psychiatric implications, ranging from learning difficulties and anxiety in childhood to a markedly elevated risk of schizophrenia in adulthood. Finally, we highlight the critical need for early detection via chromosomal microarray and the importance of lifelong, multidisciplinary management.

In this episode, we examine the lifecycle of Traumatic Brain Injury (TBI) care, ranging from acute surgical interventions and intracranial pressure monitoring to long-term cognitive rehabilitation strategies. We also discuss the latest clinical guidelines for managing severe TBI and the emerging role of blood-based biomarkers in diagnosis and prognosis.

In this episode, we explore Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common inherited kidney disorder characterized by the progressive growth of fluid-filled cysts. We break down the "two-hit" genetic model involving PKD1 and PKD2 mutations which disrupt primary cilia signaling, and discuss why Total Kidney Volume (TKV) has become the gold standard for predicting the risk of kidney failure. We also review management strategies, including the use of Tolvaptan to slow cyst growth, and examine recent research on the "Taiwan founder variant" (R803X), which reveals how specific genetic mutations influence disease severity through partial retention of channel function.

In this episode, we explore Romano-Ward syndrome, the most prevalent form of inherited Long QT syndrome (LQTS). We discuss how this genetic condition disrupts the heart's electrical recharging phase, creating a risk for life-threatening arrhythmias like Torsades de Pointes. We break down the vital genotype-specific triggers—ranging from swimming in LQT1 to sudden loud noises in LQT2—and how these insights guide personalised treatments such as beta-blockers and lifestyle modifications. Finally, we examine the hidden psychosocial toll of the condition, including the anxiety and uncertainty families face living with this unpredictable 'silent striker'.

In this episode, we investigate Congenital Cytomegalovirus (cCMV), the leading cause of non-genetic childhood sensorineural hearing loss and a significant cause of neurodevelopmental delay.

We examine the critical 21-day window for diagnosing newborns using saliva or urine PCR tests to distinguish congenital from postnatal infection. The discussion covers the debate between universal and hearing-targeted screening and the current clinical consensus on treating symptomatic infants with antivirals like valganciclovir or ganciclovir to prevent hearing deterioration.

We also explore the role of fetal MRI in detecting specific brain anomalies, such as anterior temporal lobe lesions and polymicrogyria, which help predict long-term outcomes. Finally, we highlight recent research suggesting a low risk of delayed hearing loss in purely asymptomatic infants and the promising development of a new mRNA vaccine currently in Phase 3 clinical trials.

In this episode, we explore the evolving management of cardiogenic shock (CS), a heterogeneous syndrome characterized by a ‘death spiral’ of cardiac dysfunction, systemic inflammation, and multiorgan failure. We discuss the shift from defining shock solely by hypotension to utilizing the SCAI classification system (Stages A–E) and distinct clinical phenotypes—such as cardiorenal or cardiometabolic—to stratify risk and guide therapy. We examine the cornerstone of treatment for acute myocardial infarction-CS, which remains immediate revascularization of the culprit lesion, and the preference for norepinephrine as the first-line vasopressor over dopamine to minimize arrhythmias. Finally, we analyse the controversial role of mechanical circulatory support (MCS), highlighting that while intra-aortic balloon pumps and VA-ECMO have largely failed to show survival benefits in randomized trials, recent data from the DanGer Shock trial suggests a mortality benefit for microaxial flow pumps in selected patients, despite increased safety risks.